{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:47:33Z","timestamp":1782996453355,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5428,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.nurt.2008.07.003","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T15:11:21Z","timestamp":1223133081000},"page":"542-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Therapeutic Strategies in Congenital Myasthenic Syndromes"],"prefix":"10.1016","volume":"5","author":[{"given":"Ulrike","family":"Schara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Lochm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.07.003_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.nmd.2005.05.001","article-title":"126th International Workshop: Congenital Myasthenic Syndromes, 24\u201326 September 2004, Naarden, The Netherlands","volume":"15","author":"Beeson","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.07.003_bib2","series-title":"Myology","first-page":"1801","article-title":"Congenital myasthenic syndromes","author":"Engel","year":"2004"},{"key":"10.1016\/j.nurt.2008.07.003_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2004.12.007","article-title":"Current understanding of congenital myasthenic syndromes","volume":"5","author":"Engel","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.nurt.2008.07.003_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nurt.2007.01.001","article-title":"The therapy of congenital myasthenic syndromes","volume":"4","author":"Engel","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2008.07.003_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.59.2.162","article-title":"Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes","volume":"59","author":"Croxen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.07.003_bib6","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1073\/pnas.98.4.2017","article-title":"Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans","volume":"98","author":"Ohno","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.07.003_bib7","doi-asserted-by":"crossref","first-page":"9654","DOI":"10.1073\/pnas.95.16.9654","article-title":"Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme","volume":"95","author":"Ohno","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.07.003_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1086\/302059","article-title":"Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic)","volume":"63","author":"Donger","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nurt.2008.07.003_bib9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.53.5.1076","article-title":"Chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor \u03b5-subunit gene","volume":"53","author":"Middleton","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.07.003_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/hmg\/5.9.1217","article-title":"New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome","volume":"5","author":"Engel","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.07.003_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/339465","article-title":"Rapsyn mutations in humans cause endplate acetylcholine receptor deficiency and myasthenic syndrome","volume":"70","author":"Ohno","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nurt.2008.07.003_bib12","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1093\/hmg\/ddh333","article-title":"MUSK, a new target for mutations causing congenital myasthenic syndrome","volume":"13","author":"Chevessier","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.07.003_bib13","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1126\/science.1130837","article-title":"Dok-7 mutations underlie a neuromuscular junction synaptopathy","volume":"3","author":"Beeson","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.07.003_bib14","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1073\/pnas.1230273100","article-title":"Myasthenic syndrome caused by mutation of the SCN4A sodium channel","volume":"100","author":"Tsujino","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.07.003_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00019052-200410000-00004","article-title":"Congenital myasthenic syndromes","volume":"17","author":"Hanta\u00ef","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nurt.2008.07.003_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/0883073804019003011","article-title":"Congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy","volume":"19","author":"Gurnett","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nurt.2008.07.003_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/01.wnl.0000167132.35865.31","article-title":"Congenital endplate acetylcholinesterase deficiency responsive to ephedrine","volume":"65","author":"Bestue-Cardiel","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.07.003_bib18","first-page":"818","article-title":"Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations","volume":"17","author":"Schara","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.07.003_bib19","first-page":"818","article-title":"Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations","volume":"17","author":"Schara","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.07.003_bib20","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.WNL.0000061483.11417.1B","article-title":"Treatment of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"60","author":"Harper","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.07.003_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nmd.2006.02.009","article-title":"Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"16","author":"Colomer","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.07.003_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/jnnp.54.12.1069","article-title":"3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia","volume":"54","author":"Palace","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.07.003_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90025-I","article-title":"Ephedrine: effects on neuromuscular transmission","volume":"623","author":"Sieb","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.nurt.2008.07.003_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/brain\/awm325","article-title":"Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes","volume":"131","author":"Mihaylova","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.nurt.2008.07.003_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molmed.2006.04.003","article-title":"The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy","volume":"12","author":"Miller","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nurt.2008.07.003_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.nbd.2006.04.018","article-title":"Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model","volume":"23","author":"Vohra","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nurt.2008.07.003_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ceca.2006.07.007","article-title":"Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome","volume":"41","author":"Zayas","year":"2007","journal-title":"Cell Calcium"},{"key":"10.1016\/j.nurt.2008.07.003_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/01.wnl.0000233837.79459.40","article-title":"Impaired receptor clustering in congenital myasthenic syndrome with novel RAPSN mutations","volume":"67","author":"M\u00fcller","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.07.003_bib29","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/brain\/awl188","article-title":"CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn","volume":"129","author":"M\u00fcller","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.nurt.2008.07.003_bib30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/brain\/awl200","article-title":"Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with \u2018limb-girdle myasthenia.\u2019","volume":"129","author":"Slater","year":"2006","journal-title":"Brain"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300452X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300452X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.07.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:37:42Z","timestamp":1761806262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300452X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S187874792300452X"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.07.003","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Strategies in Congenital Myasthenic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}